Overview

INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)

Status:
NOT_YET_RECRUITING

Trial end date:
2027-08-30

Target enrollment:

Participant gender:

Summary

The research team is conducting a randomized, double-blind, placebo-controlled, multicenter clinical study aimed at evaluating the impact of adding Tolecilimab (a PCSK9 inhibitor) to standard lipid-lowering therapy (statins ezetimibe) on serum lipoprotein(a) \[Lp(a)\] levels and the risk of stroke recurrence within 90 days in patients with ischemic stroke or high-risk TIA (ABCD 4) accompanied by elevated lipoprotein(a) levels (50 mg/dL).

Phase:

Details

Lead Sponsor:

Beijing Tiantan Hospital